MASH / MASLD
What a GLP-1 receptor agonist actually does: which receptors it reaches, how it slows gastric emptying, and the satiety pathway it runs through.
What is MASH / MASLD?
Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease, the 2023 renamings of NASH and NAFLD.
Liver fat with inflammation (MASH) or without (MASLD), driven by insulin resistance and obesity. SYNERGY-NASH (Loomba 2024 NEJM, tirzepatide) and ESSENCE (semaglutide phase 3) both showed substantial fibrosis improvement.
Tirzepatide trial reading list (incl. SYNERGY-NASH) →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where MASH / MASLD comes up on this site
On GLP Watchdog, MASH comes up in 1 tool.
Tools that use it
Connected terms
Other terms under Mechanism
- GLP-1 receptor
- GIP receptor
- Dual agonist
- Gastric emptying
- Food noise
- Triple agonist
- Amylin
- GLP-1 tachyphylaxis
- Non-peptide GLP-1 agonist
- A1C (glycated hemoglobin)
- TBWL (Total Body Weight Loss)
- C-peptide
- eGFR (estimated glomerular filtration rate)
- Visceral adipose tissue (VAT)
- AHI (apnea-hypopnea index)
- SNAC (oral semaglutide absorption enhancer)
Where the evidence lives
- Tirzepatide trial reading list (incl. SYNERGY-NASH)
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers